Idelalisib

Pre-clinicalTerminated

1 views this week 0 watching💤 Quiet

Interest: 18/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Absence of Signs or Symptoms

Conditions

Absence of Signs or Symptoms, B-Cell Non-Hodgkin Lymphoma, Digestive System Signs and Symptoms, Indolent Adult Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma

Trial Timeline

Feb 1, 2016 → Jun 5, 2018

NCT ID

NCT02928510

About Idelalisib

Idelalisib is a pre-clinical stage product being developed by Gilead Sciences for Absence of Signs or Symptoms. The current trial status is terminated. This product is registered under clinical trial identifier NCT02928510. Target conditions include Absence of Signs or Symptoms, B-Cell Non-Hodgkin Lymphoma, Digestive System Signs and Symptoms.

What happened to similar drugs?

1 of 4 similar drugs in Absence of Signs or Symptoms were approved

Approved (1) Terminated (0) Active (3)

🔄Brivaracetam Film-coated tablet + Brivaracetam oral solutionUCBPhase 3

🔄BrivaracetamUCBPhase 3

✅Cannabidiol (Epidiolex)Jazz PharmaceuticalsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03568929	Pre-clinical	Completed	May 25, 2018	Oct 29, 2021	Follicular Non-Hodgkin's Lymphoma Refractory
NCT02739360	Approved	Terminated	May 4, 2016	Dec 28, 2017	Lymphoid Malignancies
NCT02928510	Pre-clinical	Terminated	Feb 1, 2016	Jun 5, 2018	Absence of Signs or Symptoms
NCT02536300	Phase 3	Terminated	Jan 14, 2016	Sep 27, 2022	Follicular Lymphoma
NCT02590588	Phase 2	Terminated	Jan 1, 2016	Mar 27, 2017	Amyloidosis
NCT02242045	Phase 1	Completed	Oct 1, 2014	Oct 17, 2017	Chronic Lymphocytic Leukemia
NCT01539291	Phase 3	Terminated	Oct 3, 2012	Jun 29, 2018	Chronic Lymphocytic Leukemia
NCT01393106	Phase 2	Completed	Sep 1, 2011	Aug 1, 2014	Hodgkin Lymphoma
NCT01282424	Phase 2	Completed	Mar 18, 2011	May 16, 2018	Follicular Lymphoma
NCT01306643	Phase 1/2	Completed	Feb 1, 2011	Aug 1, 2015	Indolent Non-Hodgkin's Lymphoma
NCT01090414	Phase 1/2	Terminated	Mar 22, 2010	Jun 18, 2018	Chronic Lymphocytic Leukemia

Competing Products

9 competing products in Absence of Signs or Symptoms

See all competitors

Product	Company	Stage	Hype Score
topiramate	Johnson & Johnson	Phase 2	35
rapamune, mycophenolate mofetil and steroid + tacrolimus, sirolimus and steroid	Pfizer	Pre-clinical	26
Brivaracetam Film-coated tablet + Brivaracetam oral solution	UCB	Phase 3	47
Brivaracetam Film-coated tablet + Brivaracetam oral solution	UCB	Phase 3	40
Levetiracetam	UCB	Phase 2	35
Brivaracetam	UCB	Phase 3	44
Sativex and rifampicin + Sativex and rifampicin + Sativex and ketoconazole + Sativex and ketoconazole + Sativex and omeprazole + Sativex and omeprazole	Jazz Pharmaceuticals	Phase 1	26
Cannabidiol (Epidiolex)	Jazz Pharmaceuticals	Approved	40
BMB-101	Bright Minds Biosciences	Phase 2	36